CV Sciences (OTCQB:CVSI) had a leading voice in the FDA’s recent hearing on CBD. Held last Friday, May 31, the hearing yielded a disappointing result because no conclusive decision regarding the benefits and safety of CBD was reached. CVSI stock has fallen roughly 13% since this hearing.
Are investors put out by the FDA’s lack of acceptance for CBD? Yes. But did CV Sciences’ role in the hearing have anything to do with this? Not likely.
CVSI Stock Down Since FDA HearingFor the hearing, CV Sciences’ Senior Vice President of Science and Regulatory ...
Read The Full Article On PotStockNews.com
Get the latest marijuana stock news, cannabis on stock news on PotStockNews
All content provided by Pot Stock News is subject to our Terms Of Use and Disclaimer.